|
|
Strategy
|
Our near-term strategy is to fully develop and exploit the AerovectRx platform
technology licensed from the CDC for selected drug delivery markets. The
flexibility offered by different configurations of our device allows delivery of the
therapeutic agent to be targeted from the nasal cavity to the deep lung. We have
two product lines in development: AeroVax™ for vaccine delivery to the mucosal
tissues and AeroCell™ for respiratory therapy drug delivery. Our strategy is to
use the AeroCell™ or AeroVax™ technology to deliver known and approved
drugs to the relevant part of the airways. This targeted delivery direct to the point
of need may offer significant advantages over current modes of delivery e.g.
through oral or IV therapy.
We are actively seeking drug delivery, pharmaceutical and biotechnology
partners with which to develop inhaled delivery solutions for vaccines and other
needed therapeutics.
|
|
